HpVac is an ambitious biotechnology start-up specializing in the development of novel treatments for allergic diseases based on immunomodulatory proteins produced by the human microbiota. The team at the HpVac is a small close-knit group of experts in preclinical & clinical development, immunology, legal and finance. HpVac is always interested in applications from talented individuals, passionate about allergic diseases, science and business development to diversify and strengthen the expertise within the company.